Income Statement (TTM)
Sorrento Therapeutics, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42 | 40 | 47 | 51 | 51 | 53 | 57 | 55 | 60 | 63 | 61 | 64 |
| Change (%) | -3.68 | 16.34 | 9.68 | 0.61 | 3.06 | 7.81 | -3.60 | 9.71 | 4.17 | -3.40 | 5.87 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 115 | 121 | 145 | 176 | 194 | 220 | 242 | 239 | 262 | 255 | 234 | 222 |
| Change (%) | 5.51 | 19.48 | 21.55 | 10.31 | 13.21 | 10.24 | -1.53 | 9.81 | -2.86 | -8.15 | -5.21 | |
| % of Revenue | 276.88 | 303.31 | 311.49 | 345.20 | 378.50 | 415.76 | 425.13 | 434.25 | 434.65 | 405.29 | 385.36 | 345.01 |
| Gross Operating Profit | -73 | -81 | -98 | -125 | -143 | -167 | -185 | -184 | -202 | -192 | -173 | -157 |
| Change (%) | 10.70 | 21.02 | 27.16 | 14.27 | 16.85 | 11.01 | -0.89 | 9.84 | -4.97 | -9.70 | -9.10 | |
| % of Revenue | -176.88 | -203.31 | -211.49 | -245.20 | -278.50 | -315.76 | -325.13 | -334.25 | -334.65 | -305.29 | -285.36 | -245.01 |
| SG&A | 100 | 116 | 133 | 159 | 183 | 197 | 198 | 196 | 198 | 182 | 193 | 194 |
| Change (%) | 15.65 | 14.71 | 19.38 | 15.23 | 7.38 | 0.47 | -0.96 | 0.85 | -7.70 | 5.84 | 0.29 | |
| % of Revenue | 241.98 | 290.55 | 286.49 | 311.82 | 357.13 | 372.10 | 346.79 | 356.26 | 327.50 | 290.17 | 317.91 | 301.14 |
| R&D | ||||||||||||
| Change (%) | ||||||||||||
| % of Revenue | ||||||||||||
| OpEx | 219 | 242 | 282 | 339 | 382 | 421 | 444 | 439 | 464 | 441 | 431 | 420 |
| Change (%) | 10.07 | 16.88 | 20.24 | 12.48 | 10.26 | 5.57 | -1.27 | 5.75 | -4.88 | -2.27 | -2.68 | |
| % of Revenue | 528.52 | 603.99 | 606.78 | 665.20 | 743.70 | 795.68 | 779.18 | 797.97 | 769.16 | 702.33 | 710.55 | 653.17 |
| Operating Income | -178 | -202 | -236 | -288 | -330 | -368 | -387 | -384 | -404 | -379 | -371 | -356 |
| Change (%) | 13.28 | 16.99 | 22.32 | 14.58 | 11.38 | 5.25 | -0.93 | 5.18 | -6.23 | -2.08 | -4.08 | |
| % of Revenue | -428.52 | -503.99 | -506.78 | -565.20 | -643.70 | -695.68 | -679.18 | -697.97 | -669.16 | -602.33 | -610.55 | -553.17 |
| Interest Expense | -26 | -20 | -16 | -9 | -10 | -10 | -11 | -11 | -9 | -9 | -6 | -7 |
| Change (%) | -21.70 | -22.03 | -39.95 | 3.57 | 4.59 | 8.64 | 2.68 | -18.48 | -7.78 | -24.69 | 5.48 | |
| % of Revenue | -62.01 | -50.41 | -33.79 | -18.50 | -19.04 | -19.33 | -19.47 | -20.74 | -15.41 | -13.64 | -10.64 | -10.60 |
| Net Income | -290 | -298 | -231 | -320 | -355 | -428 | -472 | -524 | -494 | -573 | -672 | -548 |
| Change (%) | 3.00 | -22.68 | 38.51 | 11.19 | 20.52 | 10.11 | 11.06 | -5.77 | 16.06 | 17.25 | -18.41 | |
| % of Revenue | -698.01 | -746.41 | -496.04 | -626.43 | -692.36 | -809.63 | -826.96 | -952.65 | -818.24 | -911.60 | -1,106.41 | -852.65 |
Source: Capital IQ
